Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 257-262

  Powley, Mark W ^a   Frederick, Clay B ^a   Sistare, Frank D ^a   Degeorge, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE;

ANIMAL HEALTH; COMPARATIVE STUDY; GENETIC ENGINEERING; GENETIC STABILITY; HUMAN; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; COSTS AND COST ANALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; GUIDELINES AS TOPIC; HUMANS; LEGISLATION, DRUG; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; RATS; RISK ASSESSMENT; TOXICITY TESTS;

ANIMALIA;

EID: 62249100639     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx8004373     Document Type: Review

References (38)

1. Baillie, T. A., Cayen, M. N., Fouda, H., Gersons, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
2. Davis-Bruno, K. L., and Atrakchi, A. (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1563.
3. Guengerich, F. P. (2006) Safety assessment of stable drug metabolites. Chem. Res. Toxicol. 19, 1559-1560.
4. Hastings, K. L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D., and Ostertag, R. E. (2003) Letter to the Editor. Toxicol. Appl. Pharmacol. 190, 91-92.
5. Humphreys, W. G., and Under, S. E. (2006) Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem. Res. Toxicol. 19, 1564-1569.
6. Luffer-Atlas, D. (2008) Unique/major human metabolites: why, how, and when to test for safety in animals. Drug Metab. Dispos. 40, 447-463.
7. Smith, D. A., and Obach, R. S. (2005) Seeing through the MIST: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417.
8. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
9. Smith, D. A., Obach, R. S., Wiliams, D. P., and Park, B. K. (2008) Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. Chem.-Biol. Interact. [Online early access]. Published Online, September 26, 2008.
10. FDA (2008) Guidance for Industry: Safety Testing of Drug Metabolites.
11. Preuksaritanont, T., Jiunn, H. L., and Baillie, T. A. (2006) Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152.
12. Ma, X., Shah, Y., Cheung, C., Guo, G. L., Feigenbaum, L., Krausz, K. W., Idle, J. R., and Gonzalez, F. J. (2007) The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35, 194-200.
13. Scheer, N., Ross, J., Rode, A., Zevnik, B., Niehaves, S., Faust, N., and Wolf, C. R. (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J. Clin. Invest. 118, 3228-3229.
14. Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., and Evans, R. M. (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 435-439.
15. Ma, X., Cheung, C., Krausz, K. W., Shah, Y. M., Wang, T., Idle, J. R., and Gonzalez, F. J. (2008) A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab. Dispos. [Online early access]. Published Online, September 17, 2008.
16. Zuber, R., Anzenbacherova, E., and Anzenbacher, P. (2002) Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 6, 189-198.
17. Zhou, S.-F., Di, Y. M., Chan, E., Du, Y.-M., Chow, V.D.-W., Xue, C. C., Lai, X., Wang, J.-C., Li, C. G., Tian, M., and Duan, W. (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 9, 738-784.
18. Cheung, C., Ma, X., Krausz, K. W., Kimura, S., Feigenbaum, L., Dalton, T. P., Nebert, D. W., Idle, J. R., and Gonzalez, F. J. (2005) Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem. Res. Toxicol. 18, 1471-1478.
19. Derkenne, S. D., Curran, C. P., Shertzer, H, G., Dalton, T. P., Dragin, N., and Nebert, D. W. (2005) Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking wither the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet. Genomes 15, 503-511.
20. Jiang, Z. W., Dalton, T. P., Tin, L., Wang, B., Tsuneoka, Y., Shertzer, H. G., Deka, R., and Nebert, D. W. (2005) Toward the evaluation of function in genetic variability: characterizing human SNPs and establishing BAC-transgenic mice carrying the CYP1A1_CYP1A2 locus. Hum. Mutat. 25, 196-206.
21. Dragin, N., Uno, S., Wang, B., Dalton, T. P., and Neben, D. W. (2007) Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. Biochem. Biophys. Res. Commun. 359, 635-642.
22. Corchero, J., Granvil, C. P., Akiyama, T. E., Hayhurst, G. P., Pimprale, S., Feigenbaum, L., Idle, J. R., and Gonzalez, F. J. (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNFα on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 60, 1260-1267.
23. Cheung, C., Yu, A.-M., Ward, J. M., Krausz, K. W., Akiyama, T. E., Feigenbaum, L., and Gonzalez, F. J. (2005) The CYP2E1-humanized transgenic mouse: role of CYP2E1 in acetaminophen hepatotoxicity. Drug Metab. Dispos. 33, 449-457.
24. Granvil, C. P., Yu, A.-M., Elizondo, G., Akiyama, T. E., Cheung, C., Feigenbaum, L., Krausz, K. W., and Gonzalez, F. J. (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab. Dispos. 31, 548-558.
25. van Herwaarden, A. E., Smit, J. W., Sparidans, R. W., Wagenaar, E., van der Kruijssen, C. M. M., Schellens, J. H. M., Beunen, J. H., and Schinkel, A. H. (2005) Midazolam and cyclosporin A metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab. Dispos. 33, 892-895.
26. van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M. M., van Waterschoot, R. A. B., Smit, J. W., Song, J.-Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W. A., Rosing, H., Beijnen, J. H., and Schinkel, A. H. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117, 3583-3592.
27. Cheung, C., Yu, A.-M., Chen, C.-S., Krausz, K. W., Byrd, L. G., Feigenbaum, L., Edwards, R. J., Waxman, D. J., and Gonzalez, F. J. (2006) Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J. Pharmacol. Exp. Ther. 316, 1328-1334.
28. Felmlee, M. A., Lon, H.-K., Gonzalez, F. J., and Yu, A.-M. (2008) Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab. Dispos. 36, 435-441.
29. Gonzalez, F. J., and Yu, A.-M. (2006) Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol. 46, 41-64.
30. Lin, J. H. (2008) Applications and limitations of genetically modified mouse models in drug discovery and development. Current Drug Metab. 9, 419-438.
31. Muruganandan, S., and Sinal, C. J. (2008) Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin. Pharm. Ther. 83, 818-827.
32. Cheung, C., and Gonzalez, F. J. (2008) Humanized mouse lines and their application for prediction of human drug metabolism and lexicological risk assessment. J. Pharmacol. Exp. Ther. 327, 288-299.
33. van Waterschoot, R. A. B., van Herwaarden, A. E., lagas, J. S., Sparidans, R. W., Wagenaar, E., van der Kruijssen, C. M. M., Goldstein, J. A., Zeldin, D. C., Beijnen, J. H., and Schinkel, A. H. (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol. 73, 1029-1036.
34. Tiller, P. R., Yu, S., Castro-Perez, J., Fillgrove, K. L., and Baillie, T. A. (2008) High through-put, accurate mass liquid chromotagraphy/tandem mass spectrometry on a quadrupole time-of-flight system as a "first-line" approach for metabolite identification studies. Rapid Commun. Mass Spectrom. 22, 1053-1061.
35. ICH (1993) ICH harmonised tripartite guideline: Detection of toxicity to reproduction for medicinal products and toxicity to male fertility - S5(R2).
36. ICH (1997) ICH Harmonised Tripartite Guideline: Testing for carcinogenicity of pharmaceutical - S1B.
37. ICH (1998) ICH Harmonised Tripartite Guideline: Duration of chronic toxicity testing in animals (rodent and non rodent toxicity testing) - S4.
38. ICH (2000) ICH Harmonised Tripartitite Guideline: Maintenance of the ICH guideline on non clinical safety studies for the conduct of human clinical trials for pharmaceuticals - M3(R1).